IP Library Granted Patent US 9,272,025
Granted Patent B2
US 9,272,025 · App. 12/879,881 · Granted Mar 1, 2016

Increased T-cell tumor infiltration and eradication of metastases by mutant light

Inventor: Yang-Xin Fu (Chicago, IL)
Assignee: The University of Chicago
A61K39/0011C07K14/525C12N7/00A61K2039/5152A61K2039/5156A61K2039/5256A61K2039/53C07K2319/43C12N2710/10043C12N2799/022
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,272,025
App. No.
12/879,881
Granted
Mar 1, 2016
Kind
B2
Abstract

Mutant LIGHT expressed in a tumor environment elicited high levels of chemokines and adhesion molecules, accompanied by massive infiltration of naïve T lymphocytes. Methods and compositions to elicit immune responses against tumors including tumor volume reduction and eradication of metastasis using mutant LIGHT are disclosed.

Claims (1)

1. A human recombinant mutant LIGHT protein comprising the amino acid sequence of SEQ ID NO: 16, wherein the mutant LIGHT protein does not comprise the proteolytic site EQLI (SEQ ID NO: 17) located at positions 81-84 of the native human LIGHT protein sequence of SEQ ID NO: 15 and is resistant to protease digestion, and wherein the protein can be expressed on the surface of cells such that the protein functions to, reduce metastasis.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2016
From: FU, YANG-XIN
To: THE UNIVERSITY OF CHICAGO
Reel/Frame 037653/0087 →
Continuity (5)
Division 11500177 · Aug 7, 2006
Continuation In Part 10865623 · Jun 10, 2004
Provisional Application 60478126 · Jun 12, 2003
Provisional Application 60477733 · Jun 11, 2003
Related Publication 20110014152A1 · Jan 20, 2011